Ionis Pharmaceuticals Company Profile (NASDAQ:IONS)

About Ionis Pharmaceuticals

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IONS
  • CUSIP: 46433010
Key Metrics:
  • Previous Close: $44.59
  • 50 Day Moving Average: $45.82
  • 200 Day Moving Average: $39.44
  • 52-Week Range: $121,202,000.00 - $19.59
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -61.93
  • P/E Growth: -1.00
  • Market Cap: $5.40B
  • Outstanding Shares: 121,202,000
  • Beta: 2.54
  • Net Margins: -77.30%
  • Return on Equity: -120.60%
  • Return on Assets: -21.09%
  • Debt-to-Equity Ratio: 3.03%
  • Current Ratio: 6.83%
  • Quick Ratio: 6.75%
Additional Links:
Companies Related to Ionis Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $45.90 (2.94% upside)

Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateFirmActionRatingPrice TargetDetails
2/14/2017BMO Capital MarketsReiterated RatingOutperform -> Positive$63.00View Rating Details
1/8/2017Needham & Company LLCReiterated RatingBuy$64.00View Rating Details
1/6/2017Cowen and CompanyReiterated RatingHoldView Rating Details
1/6/2017Jefferies Group LLCReiterated RatingSell$17.00View Rating Details
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00View Rating Details
12/27/2016LaidlawBoost Price TargetBuy$59.00 -> $65.00View Rating Details
12/27/2016Leerink SwannBoost Price TargetMarket Perform$40.00 -> $47.00View Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHold$35.00View Rating Details
11/9/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
9/11/2016Wells Fargo & CoReiterated RatingBuyView Rating Details
8/2/2016Barclays PLCBoost Price TargetEqual Weight$26.00 -> $41.00View Rating Details
8/2/2016Morgan StanleyInitiated CoverageEqual -> Equal Weight$37.00 -> $37.00View Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$65.00 -> $48.00View Rating Details
6/22/2015Deutsche Bank AGSet Price TargetBuy$78.00View Rating Details
3/2/2015Stifel NicolausDowngradeBuy -> Hold$66.00View Rating Details
3/2/2015Brean CapitalDowngradeBuy -> HoldView Rating Details
(Data available from 2/27/2015 forward)


Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017Q416($0.12)$97.47 millionN/AView Earnings Details
11/9/2016Q316$0.08$0.06$114.65 million$110.90 millionViewListenView Earnings Details
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)
Current Year EPS Consensus Estimate: $-1.08 EPS
Next Year EPS Consensus Estimate: $-0.72 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20162($0.50)($0.45)($0.48)
Q3 20162($0.02)$0.18$0.08
Q4 20162($0.25)($0.03)($0.14)
Q1 20172($0.42)$0.85$0.22
Q2 20172($0.40)($0.31)($0.36)
Q3 20172($0.38)($0.22)($0.30)
Q4 20172($0.30)($0.13)($0.22)
(Data provided by Zacks Investment Research)


Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ionis Pharmaceuticals (NASDAQ:IONS)
Insider Ownership Percentage: 1.86%
Institutional Ownership Percentage: 87.76%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/6/2017Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
1/17/2017B Lynne ParshallCOOSell7,246$46.29$335,417.34View SEC Filing  
1/17/2017Brett P MoniaSVPSell2,502$46.29$115,817.58View SEC Filing  
1/17/2017Elizabeth L HougenCFOSell2,273$46.29$105,217.17View SEC Filing  
1/17/2017Sarah BoyceInsiderSell1,361$46.29$63,000.69View SEC Filing  
1/17/2017Stanley T CrookeCEOSell15,382$46.29$712,032.78View SEC Filing  
1/10/2017Stanley T CrookeChairmanSell13,200$49.25$650,100.00View SEC Filing  
1/4/2017Stanley T CrookeChairmanSell18,700$48.89$914,243.00View SEC Filing  
1/3/2017Brett P MoniaSVPSell309$48.60$15,017.40View SEC Filing  
12/20/2016Brett P MoniaSVPSell130$52.48$6,822.40View SEC Filing  
12/15/2016B Lynne ParshallCOOSell4,000$50.00$200,000.00View SEC Filing  
12/5/2016Elizabeth L HougenCFOSell2,500$46.05$115,125.00View SEC Filing  
12/5/2016Patrick R O'neilSVPSell350$45.00$15,750.00View SEC Filing  
12/1/2016B Lynne ParshallCOOSell12,500$42.23$527,875.00View SEC Filing  
11/14/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
11/11/2016Elizabeth L HougenSVPSell5,000$39.75$198,750.00View SEC Filing  
11/7/2016C Frank BennettSVPSell5,000$34.00$170,000.00View SEC Filing  
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.00View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.00View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.00View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.00View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.00View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.00View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.00View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.00View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.00View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.32View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.60View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.54View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.12View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.46View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.00View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.45View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.00View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.00View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.69View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.00View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.50View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.00View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.00View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.00View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.00View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.00View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.00View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.90View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.58View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.00View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.00View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.28View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.16View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.00View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.00View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.00View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.98View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.00View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.00View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.60View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.00View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.00View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
News IconInside Track: Trading Focus on Shares of Ionis Pharmaceuticals Inc (IONS) - BVN (NASDAQ:IONS) - February 25 at 12:20 AM
News IconThe Technicals For Ionis Pharmaceuticals, Inc. (IONS) Have Been Dissected (Brutally) - NY Stock News (NASDAQ:IONS) - February 25 at 12:20 AM
News IconLookout for Price Target? Owens Corning (OC), Ionis Pharmaceuticals, Inc. (IONS) - StockNewsJournal (NASDAQ:IONS) - February 25 at 12:20 AM logoIonis (IONS) Q4 Earnings: What's in the Cards for the Stock? - Nasdaq (NASDAQ:IONS) - February 22 at 6:11 PM logoIonis (IONS) Q4 Earnings: What's in the Cards for the Stock? (NASDAQ:IONS) - February 22 at 12:35 PM
News IconWhy Investors remained confident on Cooper Tire & Rubber Company (CTB), Ionis Pharmaceuticals, Inc. (IONS)? - StockNewsJournal (NASDAQ:IONS) - February 17 at 5:29 PM logoWhy Ionis Pharmaceuticals (IONS) Looks Worth the Risk - Nasdaq ... - Nasdaq (NASDAQ:IONS) - February 17 at 5:29 PM
News IconAnalytical Guide for Ionis Pharmaceuticals, Inc. (IONS), CNO ... - The USA Commerce (NASDAQ:IONS) - February 17 at 5:29 PM logoIonis Pharmaceuticals : IONS) Down on Novartis Deal (NASDAQ:IONS) - February 16 at 4:49 PM logoIonis (IONS) Enters Collaboration Agreement with Novartis (NVS) for to Develop AKCEA-APO(a)-LRx and AKCEA ... - (NASDAQ:IONS) - February 16 at 8:17 AM logoIONIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex (NASDAQ:IONS) - February 16 at 8:17 AM logoIonis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx (NASDAQ:IONS) - February 16 at 8:17 AM
News IconTrading Scope: Checking on Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - BVN (NASDAQ:IONS) - February 15 at 8:56 PM logoIonis Pharmaceuticals to Hold 2016 Financial Results Conference Call (NASDAQ:IONS) - February 15 at 8:56 PM logoIonis Pharmaceuticals (IONS) Sees Hammer Chart Pattern: Time to Buy? (NASDAQ:IONS) - February 15 at 8:56 PM logo7:02 am Ionis Pharma announces $75 mln from Bayer (BAYRY (NASDAQ:IONS) - February 15 at 12:22 AM logoIonis Pharmaceuticals : Earns $75 Million from Bayer for Advancing -FXI Rx and -FXI-L Rx (NASDAQ:IONS) - February 14 at 7:21 PM logoIonis Pharma's (IONS) IONIS-FXI Advances at Bayer, Earning $75M Milestone (NASDAQ:IONS) - February 14 at 7:21 PM logoStock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx (NASDAQ:IONS) - February 14 at 7:21 PM logoIonis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx (NASDAQ:IONS) - February 14 at 7:21 PM
News IconIonis Pharmaceuticals Inc IONS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:IONS) - February 3 at 6:31 PM logoIonis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration (NASDAQ:IONS) - February 2 at 6:38 PM logoNovartis’s Recent Developments (NASDAQ:IONS) - February 2 at 6:38 PM logoDrug could halt, reverse Alzheimer's-related damage: Washington U researchers (NASDAQ:IONS) - January 27 at 5:00 PM
News IconLooking Ahead for Ionis Pharmaceuticals Inc (NASDAQ:IONS); Are These Shares Ready to Go Higher? - Aiken Advocate (NASDAQ:IONS) - January 27 at 5:43 AM
News IconTaking a Look at the Chart for Ionis Pharmaceuticals, Inc. (IONS) - The USA Commerce (NASDAQ:IONS) - January 26 at 7:40 PM
News IconFanning the Flames: Increased Volatility Noted on Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Wall Street Beacon (NASDAQ:IONS) - January 24 at 11:44 PM
News IconInvestor Probe: Watching Technicals for Ionis Pharmaceuticals Inc. (IONS) - Springdale Times (NASDAQ:IONS) - January 24 at 11:44 PM
News IconShares Hitting The Skids, Bounding Lower Mid-Day: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Wall Street Beacon (NASDAQ:IONS) - January 23 at 6:16 PM
News IconAverage Directional Index in Review for Ionis Pharmaceuticals Inc. (IONS) - Rives Journal (NASDAQ:IONS) - January 22 at 5:47 PM
News IconInstitutions Taking Notice Of This Stock in Q4: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - Wall Street Beacon (NASDAQ:IONS) - January 20 at 4:05 PM logoIonis Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IONS) : January 20, 2017 (NASDAQ:IONS) - January 20 at 4:05 PM logoIonis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : January 19, 2017 (NASDAQ:IONS) - January 19 at 7:43 PM logoNew and Returning Bio-Tech Stock Picks for 2017 (NASDAQ:IONS) - January 17 at 1:03 PM logoBiogen's Spinraza Did Well in Phase 3 (BIIB, IONS) (NASDAQ:IONS) - January 16 at 5:56 PM
News IconQuarterly Financial Watch for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - The Newburgh Press (NASDAQ:IONS) - January 14 at 11:03 PM logoIonis Sets Sights on Volanesorsen Heart Drug (IONS) (NASDAQ:IONS) - January 13 at 7:11 PM logoWhy Ionis Pharmaceuticals Shares Fell by 22.8% in 2016 (NASDAQ:IONS) - January 13 at 7:11 PM logoIs Biogen's Stock Ready to Heat Up After a Forgettable 2016? (NASDAQ:IONS) - January 13 at 7:11 PM logoIonis Pharmaceuticals (IONS) presents at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:IONS) - January 11 at 6:35 PM logoIonis’ Stocks Surge After Novartis Deal (IONS) (NASDAQ:IONS) - January 11 at 6:35 PM logoThe 1 Biotech Stock I Want to Own in 2017 (NASDAQ:IONS) - January 11 at 6:35 PM logoBiotech Investors 'Spooked' After Trump's Comments, JMP's King Says (NASDAQ:IONS) - January 11 at 6:35 PM logoIONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Entry into a Material Definitive Agreement - Market Exclusive (NASDAQ:IONS) - January 10 at 9:46 PM logoCramer explains why the legalization of marijuana could hurt GW Pharma's value (NASDAQ:IONS) - January 9 at 9:46 PM logoBlog Coverage Novartis Joins Hands with Ionis Pharma For Cardiovascular Treatment Solutions (NASDAQ:IONS) - January 9 at 4:44 PM logoBiotech Industry Off to a Strong Start in 2017 Latest Reports on Seattle Genetics and Ionis Pharmaceuticals (NASDAQ:IONS) - January 9 at 4:44 PM logoIONIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity (NASDAQ:IONS) - January 9 at 4:44 PM logoIONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Results of Operations and Financial Condition (NASDAQ:IONS) - January 8 at 10:44 PM logoStock Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc Expects to Outclass Original 2016 Financial Guidance - Smarter Analyst (NASDAQ:IONS) - January 8 at 5:43 PM


What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?

12 brokerages have issued twelve-month price objectives for Ionis Pharmaceuticals' stock. Their forecasts range from $17.00 to $65.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $45.90 in the next twelve months.

When will Ionis Pharmaceuticals announce their earnings?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

What are analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:

  • BMO Capital Markets analysts commented, "We are incrementally more positive on IONS shares following Bayer's decision to advance FXI-Rx development. While Bayer will not assume development responsibilities until a Phase IIb dose selection study is completed, the collaboration was expanded to include next-gen LICA drug FXI-LRx, which increased the milestone payment to $75mn from $55mn. We believe the FXI program could be Ionis's most underappreciated asset, as investors assign little value and the opportunity remains upside to our and Street models, despite positive proof-of-concept data." (2/14/2017)
  • According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (2/13/2017)

  • Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)

  • Jefferies Group LLC analysts commented, "Pipeline update call focuses on volanesorsen, IONIS-GCGR-Rx & IONIS-FXI- Rx; and BIIB-partnered IONIS-DMPK-2.5-Rx discontinued due to inadequate potency in muscle in Ph1/2. Beyond highly anticipated Spinraza launch (our 2021E sales of $1.6B vs. BIIB cons of $1.4B, implying royalties to IONS of ~$250M), we view current pipeline products unlikely to drive further meaningful appreciation in IONS shares from its already hefty valuation (EV of ~$5.5B)." (1/6/2017)

Who owns Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Baillie Gifford & Co. (6.94%), State Street Corp (2.29%), Pinnacle Associates Ltd. (1.30%), Franklin Resources Inc. (0.89%) and Fiera Capital Corp (0.64%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Sarah Boyce and Stanley T Crooke.

Who sold Ionis Pharmaceuticals stock? Who is selling Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, William Harris Investors Inc., Fiera Capital Corp, Pinnacle Associates Ltd., Baillie Gifford & Co., Guggenheim Capital LLC, Raymond James Financial Services Advisors Inc. and Janus Capital Management LLC. Company insiders that have sold Ionis Pharmaceuticals stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Patrick R O'neil, Sarah Boyce and Stanley T Crooke.

Who bought Ionis Pharmaceuticals stock? Who is buying Ionis Pharmaceuticals stock?

Ionis Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Sicart Associates LLC, Deerfield Management Co., Renaissance Technologies LLC, Dimensional Fund Advisors LP, FMR LLC, Capstone Investment Advisors LLC, Franklin Resources Inc. and Russell Investments Group Ltd..

How do I buy Ionis Pharmaceuticals stock?

Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ionis Pharmaceuticals stock cost?

One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $44.59.

Ionis Pharmaceuticals (NASDAQ:IONS) Chart for Monday, February, 27, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Earnings History Chart

Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Dividend History Chart

Dividend Payments by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Last Updated on 2/27/2017 by Staff